

# Sound Biologics Announces FDA Clearance of IND Application for QLP3119

BOTHELL, WA, UNITED STATES, November 8, 2025 /EINPresswire.com/ -- [Sound Biologics](#) today announced that the U.S. Food and Drug Administration (FDA) has completed its safety review of the company's Investigational New Drug (IND) application for QLP3119 Injection ([PSB219](#)) and issued a "Study May Proceed" letter authorizing initiation of clinical testing in the United States.



This milestone reflects the strength of our preclinical package and the potential of our MabPair platform to generate differentiated dual-target antibody therapeutics."

*Wei Yan, Ph.D. CEO of Sound Biologics*

The clinical trial will be a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple subcutaneous doses of QLP3119 Injection in healthy subjects. QLP3119 simultaneously targets TSLP and IL-33, two upstream epithelial cytokines that drive overlapping but distinct inflammatory pathways contributing to airway hyper-responsiveness in the lungs. By blocking both targets, QLP3119 can achieve broader and more durable suppression of airway inflammation than single-pathway blockade. Nonclinical studies demonstrated enhanced

pharmacologic activity and a well-defined mechanism of action, supporting its advancement as a dual-specific biologic for respiratory inflammation.

"Our goal with QLP3119 is to create an effective treatment for patients with severe asthma and COPD that do not respond to current therapies." Dr. Yan added. "We look forward to advancing this promising candidate through clinical development."

## About Sound Biologics

Sound Biologics is a clinical-stage biopharmaceutical company based in Bothell, Washington, dedicated to developing innovative antibody-based therapeutics. The company's pipeline includes programs in oncology, immunology, and neurology. One of its first [MabPair](#) products, PSB205/QL1706, was approved in China in 2024 for the treatment of metastatic cervical cancer.

For more information, contact:

WEI YAN  
Sound Biologics  
+1 425-398-2021

This press release can be viewed online at: <https://www.einpresswire.com/article/865396358>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.